Back to Search Start Over

Development of a Sequence Searchable Database of Celiac Disease-Associated Peptides and Proteins for Risk Assessment of Novel Food Proteins.

Authors :
Amnuaycheewa P
Abdelmoteleb M
Wise J
Bohle B
Ferreira F
Tetteh AO
Taylor SL
Goodman RE
Source :
Frontiers in allergy [Front Allergy] 2022 May 26; Vol. 3, pp. 900573. Date of Electronic Publication: 2022 May 26 (Print Publication: 2022).
Publication Year :
2022

Abstract

Celiac disease (CeD) is an autoimmune enteropathy induced by prolamin and glutelin proteins in wheat, barley, rye, and triticale recognized by genetically restricted major histocompatibility (MHC) receptors. Patients with CeD must avoid consuming these proteins. Regulators in Europe and the United States expect an evaluation of CeD risks from proteins in genetically modified (GM) crops or novel foods for wheat-related proteins. Our database includes evidence-based causative peptides and proteins and two amino acid sequence comparison tools for CeD risk assessment. Sequence entries are based on the review of published studies of specific gluten-reactive T cell activation or intestinal epithelial toxicity. The initial database in 2012 was updated in 2018 and 2022. The current database holds 1,041 causative peptides and 76 representative proteins. The FASTA sequence comparison of 76 representative CeD proteins provides an insurance for possible unreported epitopes. Validation was conducted using protein homologs from Pooideae and non-Pooideae monocots, dicots, and non-plant proteins. Criteria for minimum percent identity and maximum E -scores are guidelines. Exact matches to any of the 1,041 peptides suggest risks, while FASTA alignment to the 76 CeD proteins suggests possible risks. Matched proteins should be tested further by CeD-specific CD4/8+ T cell assays or in vivo challenges before their use in foods.<br />Competing Interests: RG declares limited funding from six biotechnology companies from 2009 to 2012 for support of the database management. Unilever SEAC and NuSeed Americas provided limited funding to the AllergenOnline.org database from 2018 to 2021. These companies did not contribute to or see the article prior to submission. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Amnuaycheewa, Abdelmoteleb, Wise, Bohle, Ferreira, Tetteh, Taylor and Goodman.)

Details

Language :
English
ISSN :
2673-6101
Volume :
3
Database :
MEDLINE
Journal :
Frontiers in allergy
Publication Type :
Academic Journal
Accession number :
35769554
Full Text :
https://doi.org/10.3389/falgy.2022.900573